COMPARATIVE EFFECTIVENESS OF SECUKINUMAB AND INFLIXIMAB IN PSORIATIC ARTHRITIS ASSESSED BY MATCHING-ADJUSTED INDIRECT COMPARISON USING PIVOTAL PHASE 3 CLINICAL TRIAL DATA

被引：1
|
作者：
Strand, V. [1 ]
McInnes, I. [2 ]
Mease, P. [3 ,4 ]
Choy, E. [5 ]
Nash, P. [6 ]
Thom, H. [7 ]
Kalyvas, C. [8 ]
Gandhi, K. [9 ]
Pricop, L. [9 ]
Jugl, S. [10 ]
机构：
[1] Stanford Univ, Palo Alto, CA 94304 USA
[2] Univ Glasgow, Glasgow, Lanark, Scotland
[3] Swedish Med Ctr, Seattle, WA USA
[4] Univ Washington, Seattle, WA 98195 USA
[5] Cardiff Univ, Cardiff, S Glam, Wales
[6] Univ Queensland, Brisbane, Qld, Australia
[7] Univ Bristol, Bristol, Avon, England
[8] MAPI Grp, Houten, Netherlands
[9] Novartis Pharmaceut, E Hanover, NJ USA
[10] Novartis Pharma AG, Basel, Switzerland
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2017年 / 76卷
关键词：
D O I：
10.1136/annrheumdis-2017-eular.5802
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
SAT0480
引用
收藏
页码：957 / 957
页数：1
相关论文
共 50 条
  • [21] Comparative Effectiveness of Bimekizumab and Guselkumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison
    Warren, Richard B.
    Mcinnes, Iain B.
    Nash, Peter
    Grouin, Jean-Marie
    Lyris, Nikos
    Willems, Damon
    Taieb, Vanessa
    Eells, Jason
    Mease, Philip J.
    RHEUMATOLOGY AND THERAPY, 2024, 11 (03) : 829 - 839
  • [22] Correction to: Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison
    Peter Nash
    Iain B. McInnes
    Philip J. Mease
    Howard Thom
    Matthias Hunger
    Andreas Karabis
    Kunal Gandhi
    Shephard Mpofu
    Steffen M. Jugl
    Rheumatology and Therapy, 2018, 5 : 595 - 595
  • [23] Comparative Effectiveness of Bimekizumab and Risankizumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison
    Mease, Philip J.
    Warren, Richard B.
    Nash, Peter
    Grouin, Jean-Marie
    Lyris, Nikos
    Willems, Damon
    Taieb, Vanessa
    Eells, Jason
    Mcinnes, Iain B.
    RHEUMATOLOGY AND THERAPY, 2024, 11 (05) : 1403 - 1412
  • [24] SECUKINUMAB FOR THE TREATMENT OF PSORIATIC ARTHRITIS: COMPARATIVE EFFECTIVENESS RESULTS VERSUS ADALIMUMAB UP TO 48 WEEKS USING A MATCHING-ADJUSTED INDIRECT COMPARISON
    Nash, P.
    McInnes, I. B.
    Mease, P.
    Thom, H.
    Cure, S.
    Palaka, E.
    Gandhi, K.
    Mpofu, S.
    Jugl, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 353 - 354
  • [25] SECUKINUMAB SHOWS HIGHER SYMPTOMATIC IMPROVEMENT VERSUS ETANERCEPT IN PSORIATIC ARTHRITIS: COMPARATIVE EFFECTIVENESS UP TO 24 WEEKS ASSESSED BY MATCHING-ADJUSTED INDIRECT COMPARISON
    Mease, P.
    Choy, E.
    Thom, H.
    Kalyvas, C.
    Lopes, N.
    Pricop, L.
    Gandhi, K.
    Jugl, S. M.
    Nash, P.
    VALUE IN HEALTH, 2017, 20 (09) : A936 - A936
  • [26] Relative efficacy of adalimumab versus secukinumab in active psoriatic arthritis: A matching-adjusted indirect comparison
    Betts, Keith
    Mittal, Manish
    Joshi, Avani
    Song, Jinlin
    Bao, Yanjun
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB267 - AB267
  • [27] A MATCHING-ADJUSTED INDIRECT COMPARISON OF THE EFFICACY OF BIMEKIZUMAB AND SECUKINUMAB AT 52 WEEKS FOR THE TREATMENT OF PSORIATIC ARTHRITIS
    Mease, P. J.
    Warren, R. B.
    Nash, P.
    Grouin, J. M.
    Willems, D.
    Taieb, V
    Eells, J.
    McInnes, I.
    VALUE IN HEALTH, 2023, 26 (12) : S16 - S16
  • [28] Relative Efficacy of Adalimumab Versus Secukinumab in Active Psoriatic Arthritis: A Matching-Adjusted Indirect Comparison
    Betts, Keith A.
    Mittal, Manish
    Joshi, Avani
    Song, Jinlin
    Bao, Yanjun
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [29] Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison (vol 5, pg 99, 2018)
    Nash, Peter
    McInnes, Iain B.
    Mease, Philip J.
    Thom, Howard
    Hunger, Matthias
    Karabis, Andreas
    Gandhi, Kunal
    Mpofu, Shephard
    Jugl, Steffen M.
    RHEUMATOLOGY AND THERAPY, 2018, 5 (02) : 595 - 595
  • [30] SECUKINUMAB PROVIDES HIGHER SYMPTOMATIC IMPROVEMENT VERSUS ADALIMUMAB IN PSORIATIC ARTHRITIS: COMPARATIVE EFFECTIVENESS UP TO 48 WEEKS ASSESSED BY TWO MATCHING-ADJUSTED INDIRECT COMPARISONS
    Thom, H.
    Hunger, M.
    Rosal, G. F.
    Gandhi, K.
    Jugl, S. M.
    Nash, P.
    VALUE IN HEALTH, 2017, 20 (09) : A935 - A935
12345